移植相关血栓性微血管病中补体激活的体外证据。
In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy.
作者信息
Rotz Seth J, Luebbering Nathan, Dixon Bradley P, Gavriilaki Eleni, Brodsky Robert A, Dandoy Christopher E, Jodele Sonata, Davies Stella M
机构信息
Division of Bone Marrow Transplantation and Immune Deficiency and.
Division of Nephrology and Hypertension, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
出版信息
Blood Adv. 2017 Aug 23;1(20):1632-1634. doi: 10.1182/bloodadvances.2017008250. eCollection 2017 Sep 12.
Abstract
Transplantation-associated thrombotic microangiopathy is associated with complement activation in vitro.This data further supports the use of eculizumab for the treatment of patients with TA-TMA.
摘要
移植相关血栓性微血管病在体外与补体激活相关。该数据进一步支持使用依库珠单抗治疗TA-TMA患者。
相似文献
1
In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy.移植相关血栓性微血管病中补体激活的体外证据。
Blood Adv. 2017 Aug 23;1(20):1632-1634. doi: 10.1182/bloodadvances.2017008250. eCollection 2017 Sep 12.
2
Transplant-associated Thrombotic Microangiopathy Treated with Eculizumab and Romiplostim.用依库珠单抗和罗米司亭治疗移植相关血栓性微血管病
Eur J Case Rep Intern Med. 2021 Feb 10;8(3):002294. doi: 10.12890/2021_002294. eCollection 2021.
3
Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors.儿童自体造血细胞移植后血栓性微血管病：依库珠单抗治疗幸存者发生重要终末器官功能障碍的报告。
Biol Blood Marrow Transplant. 2019 May;25(5):e163-e168. doi: 10.1016/j.bbmt.2018.12.840. Epub 2019 Jan 11.
4
Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab.两例肾移植相关血栓性微血管病经依库珠单抗治疗成功
Nephrology (Carlton). 2016 Jul;21 Suppl 1:35-40. doi: 10.1111/nep.12768.
5
Hematopoietic cell transplantation-associated thrombotic microangiopathy: a review of pathophysiology, diagnosis, and treatment.造血细胞移植相关血栓性微血管病：病理生理学、诊断及治疗综述
J Blood Med. 2016 Sep 2;7:181-6. doi: 10.2147/JBM.S102235. eCollection 2016.
6
Transplantation-Associated Thrombotic Microangiopathy Risk Stratification: Is There a Window of Opportunity to Improve Outcomes?移植相关血栓性微血管病风险分层：是否有改善预后的机会窗口？
Transplant Cell Ther. 2022 Jul;28(7):392.e1-392.e9. doi: 10.1016/j.jtct.2022.04.019. Epub 2022 Apr 29.
7
Complement System as a New Target for Hematopoietic Stem Cell Transplantation-Related Thrombotic Microangiopathy.补体系统作为造血干细胞移植相关血栓性微血管病的新靶点
Pharmaceuticals (Basel). 2022 Jul 9;15(7):845. doi: 10.3390/ph15070845.
8
Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy.依库珠单抗在儿童移植相关血栓性微血管病患者中的应用。
Front Pediatr. 2021 Nov 11;9:761726. doi: 10.3389/fped.2021.761726. eCollection 2021.
9
Efficacy and Safety of Eculizumab in the Treatment of Transplant-Associated Thrombotic Microangiopathy: A Systematic Review and Meta-Analysis.依库珠单抗治疗移植相关性血栓性微血管病的疗效和安全性：系统评价和荟萃分析。
Front Immunol. 2021 Jan 20;11:564647. doi: 10.3389/fimmu.2020.564647. eCollection 2020.
10
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.依库珠单抗清除率的可变性需要进行药效学监测，以优化造血干细胞移植后血栓性微血管病的治疗。
Biol Blood Marrow Transplant. 2016 Feb;22(2):307-315. doi: 10.1016/j.bbmt.2015.10.002. Epub 2015 Oct 9.
引用本文的文献
1
Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease: A Case-Control Study.窦性阻塞综合征/静脉闭塞性疾病的遗传易感性：一项病例对照研究。
Int J Mol Sci. 2025 Jul 12;26(14):6712. doi: 10.3390/ijms26146712.
2
[Retrospective clinical analysis of eculizumab treatment for hematopoietic stem cell transplantation-associated thrombotic microangiopathy: a report of 11 cases].依库珠单抗治疗造血干细胞移植相关血栓性微血管病的回顾性临床分析：附11例报告
Zhonghua Xue Ye Xue Za Zhi. 2025 May 14;46(5):431-436. doi: 10.3760/cma.j.cn121090-20240722-00273.
3
Hemostasis and complement in allogeneic hematopoietic stem cell transplantation: clinical significance of two interactive systems.同种异体造血干细胞移植中的止血与补体：两个相互作用系统的临床意义。
Bone Marrow Transplant. 2024 Oct;59(10):1349-1359. doi: 10.1038/s41409-024-02362-8. Epub 2024 Jul 14.
4
A prospective multi-institutional study of eculizumab to treat high-risk stem cell transplantation-associated TMA.一项前瞻性多机构研究，评估依库珠单抗治疗高危干细胞移植相关性 TMA。
Blood. 2024 Mar 21;143(12):1112-1123. doi: 10.1182/blood.2023022526.
5
Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.窦房阻塞综合征/静脉阻塞性疾病的分子进展。
Int J Mol Sci. 2023 Mar 15;24(6):5620. doi: 10.3390/ijms24065620.
6
EASIX score predicts inferior survival after allogeneic hematopoietic cell transplantation.EASIX 评分预测异基因造血细胞移植后生存不良。
Bone Marrow Transplant. 2023 May;58(5):498-505. doi: 10.1038/s41409-023-01922-8. Epub 2023 Jan 31.
7
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy.补体凝集素途径在造血干细胞移植相关内皮损伤和血栓性微血管病中的作用。
Exp Hematol Oncol. 2021 Dec 19;10(1):57. doi: 10.1186/s40164-021-00249-8.
8
How I treat microangiopathic hemolytic anemia in patients with cancer.我如何治疗癌症患者的微血管病性溶血性贫血。
Blood. 2021 Mar 11;137(10):1310-1317. doi: 10.1182/blood.2019003810.
9
Ex vivo assays to detect complement activation in complementopathies.用于检测补体病中补体激活的体外试验。
Clin Immunol. 2020 Dec;221:108616. doi: 10.1016/j.clim.2020.108616. Epub 2020 Oct 24.
10
New insights into risk factors for transplant-associated thrombotic microangiopathy in pediatric HSCT.小儿造血干细胞移植相关性血栓性微血管病的危险因素新认识。
Blood Adv. 2020 Jun 9;4(11):2418-2429. doi: 10.1182/bloodadvances.2019001315.
本文引用的文献
1
ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy.ST2与内皮损伤作为移植物抗宿主病和微血管病之间的联系
N Engl J Med. 2017 Mar 23;376(12):1189-1190. doi: 10.1056/NEJMc1700185.
2
Transplant-associated thrombotic microangiopathy: opening Pandora's box.移植相关性血栓性微血管病：打开潘多拉的盒子。
Bone Marrow Transplant. 2017 Oct;52(10):1355-1360. doi: 10.1038/bmt.2017.39. Epub 2017 Mar 13.
3
New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy.儿童造血干细胞移植相关血栓性微血管病的诊断、病理生理学及治疗新方法
Transfus Apher Sci. 2016 Apr;54(2):181-90. doi: 10.1016/j.transci.2016.04.007. Epub 2016 Apr 25.
4
Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome.HELLP综合征中补体激活的直接证据：与非典型溶血性尿毒症综合征的联系。
Exp Hematol. 2016 May;44(5):390-8. doi: 10.1016/j.exphem.2016.01.005. Epub 2016 Feb 26.
5
The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy.移植相关血栓性微血管病易感性的基因指纹图谱。
Blood. 2016 Feb 25;127(8):989-96. doi: 10.1182/blood-2015-08-663435. Epub 2015 Nov 24.
6
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation.依库珠单抗清除率的可变性需要进行药效学监测，以优化造血干细胞移植后血栓性微血管病的治疗。
Biol Blood Marrow Transplant. 2016 Feb;22(2):307-315. doi: 10.1016/j.bbmt.2015.10.002. Epub 2015 Oct 9.
7
Modified Ham test for atypical hemolytic uremic syndrome.非典型溶血性尿毒症综合征的改良哈姆试验
Blood. 2015 Jun 4;125(23):3637-46. doi: 10.1182/blood-2015-02-629683. Epub 2015 Apr 10.
8
A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.一种新范式：将异基因造血干细胞移植相关血栓性微血管病诊断和管理视为多系统内皮损伤
Blood Rev. 2015 May;29(3):191-204. doi: 10.1016/j.blre.2014.11.001. Epub 2014 Nov 28.
9
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.补体激活在 aHUS 中的动力学及其如何监测依库珠单抗治疗。
Blood. 2014 Sep 11;124(11):1715-26. doi: 10.1182/blood-2014-02-558296. Epub 2014 Jul 18.
10
Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: a study in children and young adults.异基因造血干细胞移植相关血栓性微血管病的诊断和风险标准：一项针对儿童和青年的研究。
Blood. 2014 Jul 24;124(4):645-53. doi: 10.1182/blood-2014-03-564997. Epub 2014 May 29.
Zotero 插件